TransCon semaglutide | Search

Skip to main content

MedPath Trial Home

Organizations News Research

Data Sources:ClinicalTrials.govEU CTRFDAEMANMPATGAHealth CanadaWHO ICTRP

MedPath Trial Home

Search trials. Track pipelines. Understand approvals. With AI-powered intelligence for clinical research.

Product

Clinical Trials
Drug Intelligence
Global Approvals
AI Research
Pricing

Resources

FAQ
Search

Company

News
About
Contact

Legal

Privacy Policy
Terms of Service

Disclaimer: This website provides information retrieval and data analysis services. The content does not constitute medical advice. Eligibility assessments are for reference only and should not replace consultation with qualified healthcare professionals. Data is sourced from public registries and regulatory agencies; MedPath does not guarantee completeness or accuracy. Always verify information with primary sources.

© 2026 MedPath Trial. All rights reserved.

We value your privacy

We use cookies to analyze site traffic and improve your experience. See our Privacy Policy.

1,465 results for “TransCon semaglutide”

Trials

View all 700 →

A Dose Escalation Trial Evaluating Safety, Efficacy, and Pharmacokinetics of TransCon CNP Administered Once Weekly in Prepubertal Children With Achondroplasia

57 participants · First posted Sep 11, 2019

A Dose Escalation Trial Evaluating Safety, Efficacy, and Pharmacokinetics of Multiple Subcutaneous Doses of TransCon CNP Administered Once Weekly in Children With Achondroplasia

24 participants · First posted Feb 18, 2022

A Long-Term Trial Investigating Safety and Efficacy of TransCon hGH in Children With Growth Hormone Deficiency Who Have Completed a Prior TransCon hGH Clinical Trial

298 participants · First posted Nov 17, 2017

Drugs

View all 49 →

Semaglutide(Ozempic, Rybelsus, Wegovy)

Manufacturer: Novo Nordisk

Conditions: BMI >27 kg/m2, Cardiovascular Events +4 more

C₁₈₇H₂₉₁N₄₅O₅₉ · Rx

TransCon RBZ

TransCon VEGF-TKI

Organizations

Ascendis Pharma A/S

Denmark

Transcend Therapeutics

Canada

Transcode Therapeutics

United States

News

View all 708 →

Ascendis Pharma Reports Strong 2025 Performance with €720M Revenue and Advances TransCon Pipeline

TransCon hGH Meets Primary Endpoint in Turner Syndrome Trial

TransCon CNP Demonstrates Superior Growth in Achondroplasia Trial

Page 1 of 147